0000950170-24-029536.txt : 20240311 0000950170-24-029536.hdr.sgml : 20240311 20240311200232 ACCESSION NUMBER: 0000950170-24-029536 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240308 FILED AS OF DATE: 20240311 DATE AS OF CHANGE: 20240311 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wigzell Hans Lennart Rudolf CENTRAL INDEX KEY: 0001492766 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14895 FILM NUMBER: 24739842 MAIL ADDRESS: STREET 1: OSKAR BAECKSTROMSV.11 CITY: HAGERSTEN STATE: V7 ZIP: 12935 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc. CENTRAL INDEX KEY: 0000873303 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 930797222 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 415 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-274-4000 MAIL ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 415 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Sarepta Therapuetics, Inc. DATE OF NAME CHANGE: 20120712 FORMER COMPANY: FORMER CONFORMED NAME: AVI BIOPHARMA INC DATE OF NAME CHANGE: 19980930 FORMER COMPANY: FORMER CONFORMED NAME: ANTIVIRALS INC DATE OF NAME CHANGE: 19970123 4 1 ownership.xml 4 X0508 4 2024-03-08 0000873303 Sarepta Therapeutics, Inc. SRPT 0001492766 Wigzell Hans Lennart Rudolf 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142 true false false false false Common Stock 2024-03-08 4 M false 15000 13.90 A 37840 D Common Stock 2024-03-08 4 S false 3155 123.85 D 34685 D Common Stock 2024-03-08 4 S false 11745 123.10 D 22940 D Common Stock 2024-03-08 4 S false 100 122.39 D 22840 D Stock Option (right to buy) 13.90 2024-03-08 4 M false 15000 0 D 2016-02-27 2035-02-27 Common Stock 15000 0 D The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $123.6 to $124.6, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $122.65 to $123.58, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. /s/ Ryan Brown, as Attorney-in-Fact for Hans Wigzell 2024-03-11